-
In this issue: Rosiglitazone (Avandia) implicated in yet another study; Prilosec and Nexium not associated with cardiac events; Anastrozole (Arimidex) shown more effective than tamoxifen for treatment of early-stage breast cancer; antibiotics show no effect on sinusitis; FDA actions.
-
Kost and colleagues provide updated contraceptive failure rates derived from the 2002 National Survey of Family Growth.
-
-
Human Papillomavirus (HPV) testing has proved efficacious in triaging minimally abnormal cytology to further investigation or surveillance. However, despite its high sensitivity for cervix pathology, its value as a primary screening technology has been formally evaluated in only a limited way.
-
Last month an article was featured in the OB/GYN Clinical Alert from the October issue of Obstetrics & Gynecology. Since the issue was rich in good material, I will go back to it to review information pertaining to one of the most common questions asked of providers"How much weight should I gain in my pregnancy?"
-
The Collaborative Group on Epidemiological Studies of Cervical Cancer has combined and reanalyzed any relevant data from all epidemiological studies on the association between cervical carcinoma and the pattern of oral contraceptive use.
-
In the November 20th issue of the Journal of Clinical Oncology, two important articles appear, demonstrating the clinical impact of a novel therapeutic, bevacizumab, in women with recurrent ovarian cancer.
-
In this issue: FDA warnings for existing drugs dominate pharmaceutical news this month.
-
-
A majority of patients scheduled for endometrial ablation or a levonorgestrel-releasing IUD were willing to accept a 50% likelihood of treatment failure to avoid hysterectomy.
